Europas førende søgning efter kliniske forsøg

ASP3082

Clinical trials are studying ASP3082 in people with metastatic or locally advanced non-small-cell lung cancer and pancreatic ductal adenocarcinoma. These studies aim to evaluate how well the treatment works and to collect biomarker data that may help explain response and resistance.

Table of contents

Trial overview

This article is about one authorised Phase 2 clinical trial of ASP3082 in patients with metastatic or locally advanced non-small-cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).[1]

The study is described as a multicenter, open-label, interventional platform study, and its brief goal is to evaluate the efficacy of ASP3082.[1]

The trial plans to enroll 60 participants.[1]

Who can take part

The trial is designed for people with metastatic non-small-cell lung cancer or pancreatic ductal adenocarcinoma.[1]

The title also says the study includes patients with locally advanced disease, which means the cancer has grown beyond its original place but is not described here as widely spread.[1]

Because the study is multicenter, it may be available at more than one research site.[1]

What the study is measuring

The main result being measured is best overall response (BOR).[1]

BOR means the best tumor response seen during the study, based on the investigator’s assessment.[1]

The trial uses RECIST v.1.1, which is a standard method for measuring how tumors change on scans.[1]

Study design and treatment setting

The study is open label, which means the participants and the research team know which treatment is being given.[1]

It is also an interventional study, so the treatment is actively given as part of the research plan.[1]

The listed interventions include ASP3082 given intravenously and a dextrose injection / BRADEX 5% given intravenously.[1]

Biomarker analysis and why it matters

The trial includes biomarker analysis to help characterize response and resistance.[1]

Biomarkers are measurable signs in the body that can help researchers understand why a treatment works well for some people and less well for others.

This part of the study may help explain how the cancer responds during treatment and whether resistance develops.[1]

Key points for patients

  • The trial is in Phase 2, which means it is looking more closely at whether ASP3082 seems to work in patients.[1]

  • The study focuses on two cancer types: metastatic NSCLC and PDAC, with locally advanced disease also named in the title.[1]

  • The main outcome is tumor response, measured as best overall response using RECIST v.1.1.[1]

  • The study is authorised and aims to enroll 60 participants.[1]

Trial ID Phase Condition studied Status Enrollment
2025-522533-54-00 Phase 2 Metastatic non-small-cell lung cancer and pancreatic ductal adenocarcinoma Authorised 60

FAQ

  • What is being studied in the ASP3082 trials? The trials are studying ASP3082 in people with metastatic or locally advanced non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The main goal is to evaluate efficacy, which means how well the treatment works.
  • Who may be able to take part? The study is for patients with metastatic non-small-cell lung cancer or pancreatic ductal adenocarcinoma. It is a multicenter study, so it may be run at more than one hospital or clinic.
  • What phase is the ASP3082 study? This is a Phase 2 trial. Phase 2 studies usually look more closely at whether a treatment works and continue to monitor safety and response.
  • What is the main result the study is measuring? The main outcome is best overall response, or BOR. This is based on the investigator’s assessment using RECIST v.1.1, which is a standard way to measure tumor response.
  • Why are biomarker tests included? The study includes biomarker analysis to help characterize response and resistance. Biomarkers are measurable signs in the body that may help explain why a treatment works well or does not work well.

Igangværende kliniske forsøg for ASP3082

  • Undersøgelse af ASP3082 til patienter med fremskreden ikke-småcellet lungekræft og bugspytkirtelkræft med spredning til andre dele af kroppen

    Rekrutterer

    1 1 1
    Undersøgte sygdomme:
    Undersøgte lægemidler:
    Frankrig

Ordliste

  • Metastatic: Cancer that has spread from where it started to other parts of the body.
  • Locally advanced: Cancer that has grown more than at the first site and may be harder to remove, but has not clearly spread everywhere in the body.
  • Non-small-cell lung cancer (NSCLC): The most common type of lung cancer. It is often grouped together because it behaves differently from small-cell lung cancer.
  • Pancreatic ductal adenocarcinoma (PDAC): A common type of pancreatic cancer that starts in the ducts of the pancreas.
  • Phase 2: A stage of clinical research that looks more closely at whether a treatment seems to work in patients and continues to follow safety.
  • Multicenter: A study done at more than one hospital, clinic, or research site.
  • Open label: A study design where both the research team and the participants know which treatment is being given.
  • Interventional study: A study where participants receive a treatment or other intervention that is being tested.
  • Biomarker analysis: Testing body samples to look for signs that may help explain how a treatment is working or why it is not working.
  • Response: How much a cancer shrinks, stays the same, or grows during treatment.
  • Resistance: When a cancer does not respond well to a treatment or stops responding over time.
  • RECIST v.1.1: A standard system doctors use in trials to measure changes in tumors on scans.

Referencer

  1. https://clinicaltrials.gov/study/2025-522533-54-00